Renovacor, Inc.

Chardan Healthcare Acquisition 2 Corp. (Nasdaq: CHAQ), a blank-check company sponsored by Chardan, completed its business combination with Renovacor, Inc., a clinical-stage biopharmaceutical company developing gene therapies for cardiovascular disease. CHAQ went public in 2020 with a focus on the healthcare and life sciences sector, and announced its definitive merger agreement with Renovacor in March 2021. Renovacor's lead program targeted genetic forms of heart failure, placing the combined entity squarely within the biotech and pharma space. The transaction has since closed, marking the conclusion of CHAQ's life cycle as a public SPAC vehicle. Sign up at SpacDesk for full deal timelines, filing history, and sponsor data on CHAQ and hundreds of other SPACs.

SPAC Counterparty (1)